Lower Breast Cancer Mortality Seen With Estrogen Use

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

SAN FRANCISCO--Use of estrogen supplements may lower breast cancer mortality, an American Cancer Society study has shown. The study, which was discussed at the ACS's science writers meeting, followed 400,000 women who provided data about their cancer risk factors. After 9 years, breast cancer mortality was 16% lower in those women who used estrogen, suggesting that their tumors were less aggressive.

SAN FRANCISCO--Use of estrogen supplements may lower breast cancermortality, an American Cancer Society study has shown. The study,which was discussed at the ACS's science writers meeting, followed400,000 women who provided data about their cancer risk factors.After 9 years, breast cancer mortality was 16% lower in thosewomen who used estrogen, suggesting that their tumors were lessaggressive.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content